Security National Bank Purchases 37,045 Shares of Boston Scientific Corporation (NYSE:BSX)

Security National Bank boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 1,744.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 39,169 shares of the medical equipment provider's stock after purchasing an additional 37,045 shares during the quarter. Security National Bank's holdings in Boston Scientific were worth $3,951,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Perigon Wealth Management LLC grew its holdings in Boston Scientific by 7.9% in the first quarter. Perigon Wealth Management LLC now owns 13,532 shares of the medical equipment provider's stock worth $1,365,000 after purchasing an additional 996 shares during the period. HBK Sorce Advisory LLC grew its holdings in shares of Boston Scientific by 3.2% during the first quarter. HBK Sorce Advisory LLC now owns 8,286 shares of the medical equipment provider's stock valued at $836,000 after buying an additional 254 shares during the last quarter. Pinnacle Bancorp Inc. grew its holdings in shares of Boston Scientific by 20.2% during the first quarter. Pinnacle Bancorp Inc. now owns 1,255 shares of the medical equipment provider's stock valued at $127,000 after buying an additional 211 shares during the last quarter. Golden State Wealth Management LLC grew its holdings in shares of Boston Scientific by 37.0% during the first quarter. Golden State Wealth Management LLC now owns 1,674 shares of the medical equipment provider's stock valued at $169,000 after buying an additional 452 shares during the last quarter. Finally, Spire Wealth Management grew its holdings in shares of Boston Scientific by 15.9% during the first quarter. Spire Wealth Management now owns 10,630 shares of the medical equipment provider's stock valued at $1,072,000 after buying an additional 1,456 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other news, EVP John Bradley Sorenson sold 4,572 shares of the business's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the sale, the executive vice president now owns 18,705 shares of the company's stock, valued at $1,955,420.70. The trade was a 19.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares in the company, valued at approximately $3,441,592.37. This trade represents a 11.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 411,970 shares of company stock worth $42,406,693 over the last three months. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

BSX traded up $2.25 during midday trading on Friday, reaching $106.83. The company had a trading volume of 15,636,958 shares, compared to its average volume of 6,623,509. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45. The stock has a market cap of $158.05 billion, a PE ratio of 77.98, a P/E/G ratio of 2.75 and a beta of 0.68. Boston Scientific Corporation has a 12-month low of $71.88 and a 12-month high of $107.17. The business has a 50-day moving average price of $102.74 and a two-hundred day moving average price of $99.68.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The company's quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.56 earnings per share. On average, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Needham & Company LLC reiterated a "buy" rating and set a $115.00 price objective on shares of Boston Scientific in a report on Wednesday, May 28th. Erste Group Bank upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Citigroup reiterated a "buy" rating and set a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Finally, Robert W. Baird lifted their price objective on shares of Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Twenty-two analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $116.09.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.